OPC-28326, 4-(N-methyl-2-phenylethylamino)-1-(3,5-dimethyl-4-propionyl-aminobenzoyl)
piperidine hydrochloride monohydrate, is a newly developed selective peripheral
vasodilator and increases blood flow to lower extremities with alpha2-adrenergic antagonist property. Here, we investigated the effect of
OPC-28326 on
ischemia-induced angiogenesis.
OPC-28326 enhanced tube formation by human aortic endothelial cells (HAECs). Moreover,
OPC-28326 enhanced the number of microvessels sprouting from aortic rings embedded in
collagen gel.
OPC-28326 markedly induced phosphorylation of
endothelial nitric oxide synthase (eNOS) in HAECs via phosphatidylinositol-3
kinase PI3K/Akt (PI3K/Akt) pathway. Next, the angiogenic effect of
OPC-28326 was evaluated in a mouse hindlimb
ischemia model. Blood flow recovery to the ischemic leg was significantly enhanced by
OPC-28326. Furthermore, anti-CD31 immunostaining revealed that
OPC-28326 increased capillary density in the ischemic muscle. However,
OPC-28326 failed to promote blood flow recovery in ischemic hindlimb in eNOS-deficient mice. These results suggest that
OPC-28326 promotes angiogenesis, which was associated with activation of eNOS via PI3K/Akt pathway.
OPC-28326 might be promising to treat patients with ischemic
vascular diseases.